在一项抗体导向酶前体药物疗法（ADEPT）临床研究中对前体药物、活性药物及代谢产物的鉴定。
Identification of prodrug, active drug, and metabolites in an ADEPT clinical study.
作者信息
Springer C J, Poon G K, Sharma S K, Bagshawe K D
机构信息
Department of Medical Oncology, Charing Cross Hospital, London, England.
出版信息
Cell Biophys. 1993 Jan-Jun;22(1-3):9-26. doi: 10.1007/BF03033864.
Antibody-directed enzyme prodrug therapy (ADEPT) involves two phases. The first is an antibody-enzyme conjugate that localizes to tumor. The second phase is a prodrug that is administered when the enzyme-conjugate has cleared from blood and other nontumor tissues. In the pilot-scale clinical trial, the prodrug has been measured--in the plasma of patients, by liquid chromatography (HPLC) and by liquid chromatography-mass spectrometry (LC-MS). Active drug has been detected and metabolites identified. An indirect measurement of enzyme-conjugate in the plasma of patients has also been developed.
抗体导向酶前药疗法（ADEPT）包括两个阶段。第一阶段是一种抗体 - 酶偶联物，它会定位于肿瘤部位。第二阶段是在前药，当酶偶联物已从血液和其他非肿瘤组织中清除后给予。在中试规模的临床试验中，通过液相色谱法（HPLC）和液相色谱 - 质谱法（LC - MS）在患者血浆中对前药进行了测定。已检测到活性药物并鉴定出代谢产物。还开发了一种对患者血浆中酶偶联物的间接测量方法。
Zotero 插件